Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has transferred approximately 38.6% of its issued shares in Bausch + Lomb Corporation to a wholly-owned unrestricted subsidiary. The Company retains 50.1% of Bausch + Lomb, maintaining an overall 88.7% ownership. This transfer aligns with Bausch Health's plan for the separation of Bausch + Lomb, providing strategic flexibility while evaluating options. The separation is subject to lockup expirations, debt leverage ratios, and necessary approvals.
KBRA has released its latest U.S. Bank Compendium, analyzing the 2Q22 results for U.S. banks rated by KBRA amidst rising interest rates. The report discusses how banks are adjusting to these changes and potential impacts on profitability amid economic uncertainty. Key performance metrics, including credit ratios and returns on assets, are highlighted. The Compendium also provides a quarterly ESG Bulletin featuring Univest Financial Corporation (NASDAQ: UVSP) along with summaries of all publicly traded banks in KBRA's rated universe.
Bausch Health Companies (NYSE/TSX: BHC) announced that the U.S. District Court in Delaware upheld certain patents for XIFAXAN® (rifaximin) 550 mg while invalidating others. The company plans to appeal this decision, with expectations for the appeal to conclude in 12 to 18 months. Currently, Norwich Pharmaceuticals cannot launch a generic version of XIFAXAN until it receives FDA approval for a revised application that excludes the XIFAXAN HE indication. XIFAXAN is indicated for treating IBS-D and preventing hepatic encephalopathy recurrence.
Bausch Health Companies Inc. (BHC) announced support for the new ICD-10 code K76.82 for hepatic encephalopathy (HE), effective October 1, 2022. This code aims to enhance diagnosis and treatment for the rising number of chronic liver disease cases in the U.S., where approximately 4.5 million adults are affected. HE, a complication of cirrhosis, can lead to increased hospitalizations and readmissions. The new code will assist healthcare providers in accurately documenting HE, thereby improving patient care.
Bausch Health Companies Inc. reported second-quarter 2022 revenues of $1.967 billion, down 6% from $2.1 billion in Q2 2021. The decline was attributed to foreign exchange impacts and divestitures. The company's net loss decreased to $145 million compared to $595 million the previous year. Operating income improved significantly to $161 million. Bausch Health is appealing a court decision concerning XIFAXAN patent litigation and is committed to strategic alternatives, including a potential spinoff of Bausch + Lomb, despite ongoing challenges.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to appeal a recent U.S. District Court ruling regarding its XIFAXAN® patents. The court ruled the patents for the treatment of overt hepatic encephalopathy as valid but declared those for irritable bowel syndrome with diarrhea invalid. Bausch intends to challenge this ruling vigorously and prevent Norwich Pharmaceuticals from launching a generic version of XIFAXAN® until at least 2029. The FDA is also revising guidance for rifaximin, which may impact future generic approvals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its second-quarter financial results on August 9, 2022, at 8:00 a.m. ET. A conference call and live webcast will follow, providing insights into the company's performance and business updates. Interested parties can access the materials through the Investor Relations section of Bausch Health's website. The company is focused on improving lives through its diverse portfolio in various health sectors, including gastroenterology and dermatology.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has appointed Thomas W. Ross, Sr. as the new chair of the Board of Directors following the resignation of Joseph C. Papa. Mr. Papa remains CEO until a successor is found. The Board is actively searching for a new CEO while affirming the company's full-year guidance for 2022, initially announced on June 8. The company aims to complete its spinoff from Bausch Health (NYSE/TSX: BHC) in 2023, contingent on various approvals and market conditions, with no reported disagreements leading to Mr. Papa's departure.
Bausch Health Companies Inc. (NYSE/TSX: BHC) and Salix Pharmaceuticals announced the winners of the 2022 Salix Gastrointestinal Health Scholars Program, awarding $10,000 each to 10 students living with gastrointestinal diseases. This marks the third consecutive year of the program which received over 150 applications. The scholarship aims to assist students in their academic pursuits amid health challenges. The recipients span undergraduate and graduate categories, showcasing the company's commitment to supporting education for those impacted by GI conditions.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the results of its 2022 annual meeting of shareholders held on June 21, 2022. All 12 nominated directors were elected, with Thomas J. Appio as CEO expressing gratitude towards former Board member Joseph C. Papa who resigned. John A. Paulson fills the vacancy and will serve as Board Chair. Shareholders approved executive compensation, amendments to the 2014 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent auditor until the 2023 meeting. Full voting results will be reported on Form 8-K.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
